These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1469957)

  • 21. [Value of the theory of the optimal sampling scheme for bioequivalence studies].
    Tod M; Petitjean O; Nicolas P
    Therapie; 1993; 48(1):7-13. PubMed ID: 8356559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The pharmacokinetics and bioequivalence of various dosage forms of ambroxol].
    Vergin H; Bishop-Freudling GB; Miczka M; Nitsche V; Strobel K; Matzkies F
    Arzneimittelforschung; 1985; 35(10):1591-5. PubMed ID: 4074420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reference tables for the intrasubject coefficient of variation in bioequivalence studies.
    Steinijans VW; Sauter R; Hauschke D; Diletti E; Schall R; Luus HG; Elze M; Blume H; Hoffmann C; Franke G
    Int J Clin Pharmacol Ther; 1995 Aug; 33(8):427-30. PubMed ID: 8556220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPLC analysis of theophylline: bioequivalence study of two sustained-release formulations at steady state.
    Mazzei M; Sottofattori E; Balbi A; Bottino GB
    Farmaco; 1992 May; 47(5 Suppl):769-77. PubMed ID: 1524625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren].
    Honorato J; Montes B; Suárez J; Lucero ML; Valiente R
    Rev Med Univ Navarra; 1992; 37(1):7-16. PubMed ID: 1626168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vivo verification of in vitro release specifications of a theophylline sustained-release preparation].
    von Nieciecki A; Fuchs WS; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):580-3. PubMed ID: 9676348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single dose cross-over theophylline bioavailability study.
    Walker SE; Paton TW; Iazzetta J
    Br J Clin Pract; 1983 Jan; 37(1):23-7. PubMed ID: 6838753
    [No Abstract]   [Full Text] [Related]  

  • 28. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.
    Delrat P; Paraire M; Jochemsen R
    Biopharm Drug Dispos; 2002 May; 23(4):151-7. PubMed ID: 12015789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and bioavailability of four modified-release ursodeoxycholic acid preparations for once-a-day administration.
    Simoni P; Sabatini L; Baraldini M; Mirasoli M; Roda A; Roda E
    Int J Clin Pharmacol Res; 2002; 22(2):37-45. PubMed ID: 12503774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability and bioequivalence requirements in the European community.
    Rauws AG
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():519-32. PubMed ID: 1820933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
    Tompson DJ; Vearer D
    Clin Ther; 2007 Dec; 29(12):2654-66. PubMed ID: 18201581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and bioequivalence of different formulations of pirenzepine.
    Vergin H; Mascher H; Strobel K; Nitsche V
    Arzneimittelforschung; 1986 Sep; 36(9):1409-12. PubMed ID: 3790194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.
    Zhao Q; Janssens L; Verhaeghe T; Brashear HR; Truyen L
    Curr Med Res Opin; 2005 Oct; 21(10):1547-54. PubMed ID: 16238894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis.
    Savoie N; Booth BP; Bradley T; Garofolo F; Hughes NC; Hussain S; King SP; Lindsay M; Lowes S; Ormsby E; Phull R; Rocci ML; Vallano PT; Viau A; Zhu Z
    Bioanalysis; 2009 Apr; 1(1):19-30. PubMed ID: 21083184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
    Jaminet F
    J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
    [No Abstract]   [Full Text] [Related]  

  • 38. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.
    Shah VP; Midha KK; Dighe S; McGilveray IJ; Skelly JP; Yacobi A; Layloff T; Viswanathan CT; Cook CE; McDowall RD
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):249-55. PubMed ID: 1823867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The bioavailability and bioequivalence of dignoxin and digitoxin preparations].
    Weyers W; Meinecke M; Brodbeck R
    Pharm Acta Helv; 1979; 54(6):173-9. PubMed ID: 515104
    [No Abstract]   [Full Text] [Related]  

  • 40. [Injectable and implantable drug delivery systems].
    Iga T
    Nihon Rinsho; 1989 Jun; 47(6):1261-7. PubMed ID: 2769988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.